These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38933821)

  • 1. Gluco-regulation & type 2 diabetes: entrenched misconceptions updated to new governing principles for gold standard management.
    Schwartz SS; Herman ME
    Front Endocrinol (Lausanne); 2024; 15():1394805. PubMed ID: 38933821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective.
    Saisho Y
    Expert Opin Pharmacother; 2020 Sep; 21(13):1565-1578. PubMed ID: 32521177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Serowik TC; Pantalone KM
    J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
    van Raalte DH; Verchere CB
    Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
    Deng S; Zhao H; Chai S; Sun Y; Shen P; Lin H; Zhan S
    Front Endocrinol (Lausanne); 2024; 15():1369908. PubMed ID: 38803473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The residual cardiorenal risk in type 2 diabetes.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
    Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
    Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
    Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
    [No Abstract]   [Full Text] [Related]  

  • 14. Type 2 Diabetes.
    Crawford AL; Laiteerapong N
    Ann Intern Med; 2024 Jun; 177(6):ITC81-ITC96. PubMed ID: 38857502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors: impact on glucose metabolism.
    Boj-Carceller D
    Endocrine; 2013 Feb; 43(1):22-32. PubMed ID: 22886351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
    Johansson KS; Brønden A; Knop FK; Christensen MB
    Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines.
    Schwartz SS; Corkey BE; R Gavin J; DeFronzo RA; Herman ME
    BMC Med; 2024 Sep; 22(1):356. PubMed ID: 39227924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications.
    Wysham C; Shubrook J
    Postgrad Med; 2020 Nov; 132(8):676-686. PubMed ID: 32543261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.